Brooks Laboratories Ltd has appointed Mr. Rajesh Mahajan as President - Trading and Senior Management Personnel effective July 17, 2026. The appointment aims to leverage his extensive expertise in pharmaceutical formulations and manufacturing operations to drive the company's formulation business and new project initiatives.

The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the required details in compliance with SEBI Master Circular No. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Mr. Rajesh Mahajan holds a Bachelor's Degree in Biology and an MBA in Marketing. He possesses over 20 years of experience in the pharmaceutical industry, with a specific focus on formulations and manufacturing operations. His previous contributions include playing a key role in the growth of Brooks Laboratories 's formulation business and executing business development strategies.

The appointment details were formally communicated to BSE Limited and the National Stock Exchange of India Ltd. The information has been made available on the company's official website.

Key Appointment Details

Brooks Laboratories Limited has incorporated a wholly owned subsidiary named Abridge Speciality Limited on July 2, 2026, to expand its business operations in the pharmaceutical sector. The Certificate of Incorporation was issued by the Ministry of Corporate Affairs on the same day. This strategic move aims to broaden the company's corporate structure and enhance its manufacturing and marketing capabilities.

Abridge Speciality Limited has been established with an authorised share capital of ₹1,00,000. As a newly incorporated entity, it has not yet commenced business operations, making details regarding turnover and net worth not applicable. The subsidiary is classified as a related party transaction, with Brooks Laboratories Limited acting as the promoter holding 100% of the share capital.

The initial share capital was subscribed at face value at the time of incorporation. No specific governmental or regulatory approvals were required for this establishment. The company has disclosed that no further indicative time period is needed for completion as the entity is already fully incorporated.

Key Details of Abridge Speciality Limited

The information regarding the incorporation was submitted to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was signed by Krutika Rane, Company Secretary and Compliance Officer for Brooks Laboratories .